First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial
Liver Cancer · 14.11.2024 · 14 (4) · 365-377
DOI: 10.1159/000542572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer, online erschienen am 14.11.2024. Verfasst von Masatoshi Kudo und 16 weiteren Autor:innen. Beteiligte Einrichtung: Kindai University Hospital, Osaka, Japan. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
The phase 3 LEAP-002 study (NCT03713593) of advanced hepatocellular carcinoma (HCC) suggested improved antitumor activity of lenvatinib plus pembrolizumab versus lenvatinib alone with manageable safety, although overall survival (OS) and progression-free survival (PFS) did not reach prespecified statistical significance. This post hoc analysis assessed efficacy and safety in Japanese patients.
Methods
Patients with advanced HCC without prior systemic treatment were randomly assigned 1:1 to receive 8 mg (body weight
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Kindai University Hospital, Osaka, Japan.
- National Cancer Center Hospital East, Kashiwa, Japan.
- Hiroshima Prefectural Hospital, Hiroshima, Japan.
- Yokohama City University Medical Center, Yokohama, Japan.
- Japanese Red Cross Osaka Hospital, Osaka, Japan.
- Toranomon Hospital, Tokyo, Japan.
Zitieren
APA
Kudo, M., Ikeda, M., Aikata, H., Numata, K., Marusawa, H., Hosaka, T., Kato, N., Kurosaki, M., Morimoto, M., Yamashita, T., Koga, H., Masaki, T., Yatsuzuka, N., Suzuki, M., Nagao, S., Kaneko, S., & Kumada, H. (2024). First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. Liver Cancer, 14(4), 365-377. https://doi.org/10.1159/000542572
Vancouver
Kudo M, Ikeda M, Aikata H, Numata K, Marusawa H, Hosaka T, et al. First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial. Liver Cancer. 2024;14(4):365-377. doi:10.1159/000542572
BibTeX
@article{Kudo2024,
author = {Kudo, Masatoshi and Ikeda, Masafumi and Aikata, Hiroshi and Numata, Kazushi and Marusawa, Hiroyuki and Hosaka, Tetsuya and Kato, Naoya and Kurosaki, Masayuki and Morimoto, Manabu and Yamashita, Tatsuya and Koga, Hironori and Masaki, Tsutomu and Yatsuzuka, Naoyoshi and Suzuki, Masato and Nagao, Satoshi and Kaneko, Shuichi and Kumada, Hiromitsu},
title = {First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial},
journal = {Liver Cancer},
year = {2024},
volume = {14},
number = {4},
pages = {365--377},
doi = {10.1159/000542572}
}
EUVIMED